MISSISSAUGA, Ontario, Jan. 29, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on March 13, 2026, to shareholders of record at the close of business on February 27, 2026. This first quarter 2026 dividend represents a 10% increase from the fourth quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an 'eligible ...

Core Viewpoint - Unicycive Therapeutics (UNCY) is being initiated with a "Buy" rating due to the FDA's acceptance of its resubmission of the New Drug Application (NDA) for oxylanthanum carbonate (OLC) for review [2] Company Overview - Unicycive Therapeutics focuses on developing innovative therapies in the pharmaceutical sector, particularly in the area of phosphate binders [2] - The company aims to generate long-term value in the healthcare market through its product pipeline and strategic initiatives [2] Market Context - The acceptance of the NDA for OLC represents a significant milestone for Unicycive, potentially positioning the company favorably within the biotech industry [2] - The Biotech Analysis Central service provides extensive resources, including a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks, which can aid investors in making informed decisions [2]

Core Viewpoint - Teva Pharmaceutical Industries is experiencing a positive outlook due to strong financial performance and an increased price target from Scotiabank, indicating potential growth opportunities for investors [2][4][5] Financial Performance - Teva reported a significant increase in its fourth-quarter profit, driven by strong sales of branded drugs and a milestone payment for treatments related to ulcerative colitis and Crohn's disease [2][5] - The company's current market capitalization is approximately $37.31 billion, reflecting its substantial presence in the pharmaceutical industry [4] Stock Performance - The current stock price of TEVA is $32.54, which has seen a decrease of 2.03% with a change of $0.68 [3][5] - TEVA's stock has fluctuated between a low of $32.19 and a high of $33.43 today, with the highest price over the past year being $33.43 and the lowest at $12.47, indicating volatility and growth potential [3][5] Analyst Ratings - Scotiabank maintains an "Outperform" rating for TEVA and has raised its price target from $35 to $40, reflecting an optimistic outlook for the company's future performance [2][5] - The trading volume for TEVA today is 2,763,304 shares, indicating active investor interest [4]

Core Insights - Johnson & Johnson (JNJ) is recognized as a Dividend King, having consistently paid and increased dividends for over 50 years, making it a stable investment option during market volatility [1] - JNJ stock outperformed the market with a 43.7% increase last year, compared to the market's overall gain of 16.6%, and has continued to rise by over 10% in early 2026 [2] Business Structure and Performance - In 2023, JNJ spun off its consumer division into a separate company called Kenvue (KVUE), allowing JNJ to focus on a pure-play health care innovation business centered on drugs and medical devices [4] - The Innovative Medicine segment is the primary revenue driver, generating $15.7 billion in Q4 2023, a 10% year-over-year increase, and $60.4 billion for the full year, reflecting a 6% increase [4] - JNJ reported a 5.3% increase in worldwide sales to $94.2 billion, despite challenges from the loss of exclusivity on Stelara, with adjusted diluted earnings per share rising 8.1% to $10.79 [4] Growth Prospects - Oncology is projected to achieve 21% operational sales growth in 2025, with anticipated annual sales exceeding $50 billion by 2030, marking it as a significant growth engine for the company [5] - The MedTech segment also showed strong performance, with a 7.5% revenue growth in Q4 and 6.1% for the full year, generating $34 billion in sales, driven by advancements in Cardiovascular, Surgery, and Vision [5] - JNJ's MedTech division is supported by over 60 active clinical trials and multiple regulatory submissions planned, positioning it as a key growth pillar alongside Pharmaceuticals [5][6]

Core Insights - The biotech M&A market is experiencing significant growth as pharmaceutical companies face a patent cliff that could result in a loss of $200 billion to $250 billion in branded medicine sales by 2032 [1] - A projected 15% increase in both the number of acquisitions and total deal value is expected by 2026, with approximately 520 transactions totaling $230 billion [1] - Investors are encouraged to focus on mid-cap biotech companies with drugs in advanced clinical trials, as 80% of expected deals will target these more advanced treatments [1] Biotech Fund Overview - The ALPS Medical Breakthroughs ETF (SBIO) is positioned to benefit from this M&A wave, holding companies that have at least one drug in Phase II or Phase III FDA clinical trials [1] - SBIO's portfolio includes 87 holdings with a total of 205 drugs in Phase II trials and 118 in Phase III trials [1] Market Opportunities - Major chronic disease markets such as diabetes and kidney disease are highlighted, with 589 million people living with diabetes and 850 million affected by kidney disease globally [1] - SBIO includes companies like MannKind Corporation, which reported fourth-quarter revenue exceeding $100 million, and others focused on obesity and rare kidney diseases [1] Performance Metrics - SBIO has achieved a 58.5% gain over the past year, outperforming all ALPS ETF products for 2025 [1] - The fund ended December with $141.9 million in assets under management and has a 0.50% expense ratio [1] Market Conditions - Reduced uncertainty in the U.S. market is noted following pricing agreements with branded pharmaceutical companies, alongside expected Federal Reserve rate cuts in 2026 that will lower acquisition costs [1]

Core Insights - Organon & Co. has completed the divestiture of its JADA System to Laborie Medical Technologies for up to $465 million, which includes $440 million paid at closing and a potential earn-out of up to $25 million based on 2026 revenue targets [1][7] Company Developments - The JADA team has assisted over 136,000 women across more than 20 countries, establishing JADA as a widely accepted treatment for postpartum hemorrhage [2][8] - The divestiture is expected to strengthen Organon's balance sheet and support its capital allocation strategy for growth opportunities in women's health biopharmaceuticals [2][4] - The net proceeds from the sale will likely be used for debt reduction, aligning with Organon's goal to lower its net-debt-to-adjusted EBITDA ratio, thereby enhancing its capacity for targeted reinvestment or acquisitions [4][9] Market Performance - Following the announcement of the divestiture, Organon shares declined by 1.2%, with a total decline of 11.5% over the past six months, contrasting with the industry's growth of 12.6% and the S&P 500's rise of 12.2% [3] Industry Context - The postpartum hemorrhage treatment market was valued at $1.6 billion in 2025 and is projected to grow at a CAGR of 5.3% through 2032, driven by factors such as rising maternal mortality rates and the standardization of PPH care bundles in hospitals [11]

U.S. President Donald Trump said on Thursday that he has spoken to the head of pharmaceutical company Eli Lilly and that the company plans to build six plants in the country. ...

Earnings Reports - A number of major companies are set to report earnings in the first week of February, including Alphabet (GOOGL), Amazon (AMZN), Eli Lilly (LLY), PayPal (PYPL), PepsiCo (PEP), Pfizer (PFE), Shopify (SHOP), Snap (SNAP), Strategy (MSTR), Take-Two Interactive (TTWO), Tapestry (TPR), Tyson Foods (TSN), Qualcomm (QCOM), Uber (UBER), and Walt Disney (DIS) [1] Economic Data - The week will feature key economic data releases, starting with auto sales and the ISM manufacturing index on Monday, February 2 [2] - Job openings and the ISM services index are scheduled for Tuesday, February 3 [2] - ADP employment data will be released on Wednesday, February 4 [2] - Regularly scheduled jobs data will be available on Thursday, February 5, along with a speech from Atlanta Fed President Raphael Bostic [2] - The employment report, hourly wages, consumer sentiment, and consumer credit data will be released on Friday, February 6 [3]

Core Insights - Halozyme Therapeutics (HALO) shares increased nearly 4% after the release of preliminary full-year 2025 results that exceeded expectations, along with an upward revision of sales and EPS guidance for 2026 [1][6]. Financial Performance - Preliminary revenues for full-year 2025 are projected to be between $1.39 billion and $1.40 billion, reflecting a year-over-year growth of 36% to 38%, surpassing previous guidance of $1.30 billion to $1.38 billion and the Zacks Consensus Estimate of $1.35 billion [4]. - Anticipated royalty revenues for 2025 are expected to be in the range of $865 million to $870 million, indicating a year-over-year growth of 51% to 52% [5]. 2026 Guidance - For 2026, total revenues are expected to be between $1.71 billion and $1.81 billion, representing a growth of 23% to 30% over projected 2025 revenues [6]. - Royalty revenues for 2026 are now anticipated to be between $1.13 billion and $1.17 billion, implying a year-over-year growth of 30% to 35%, ahead of previous expectations of $900 million to $940 million [7]. - Adjusted earnings per share for 2026 are projected to be between $7.75 and $8.25, an increase from earlier projections of $6.50 to $7.00 [8]. Strategic Developments - The raised guidance for adjusted EBITDA and earnings per share includes a financial impact of approximately $60 million from the acquisition of Hypercon and Surf Bio technologies, which were not included in earlier guidance [9]. - By the end of 2026, the company expects to have 15 partner programs in development and aims to sign three or more new drug-delivery licensing agreements [10]. Market Performance - Over the past year, shares of Halozyme have increased by 29.1%, compared to the industry growth of 15.6% [2].

Core Insights - Sanofi reported fourth-quarter 2025 adjusted earnings of 89 cents per American depositary share, exceeding the Zacks Consensus Estimate of 84 cents, with earnings of €1.53 per share reflecting a 16.8% increase on a reported basis and a 26.7% increase on a constant currency rate basis, primarily due to cost control [1] - Net sales increased by 7.0% on a reported basis to $13.2 billion (€11.3 billion), although slightly missing the Zacks Consensus Estimate of $13.4 billion [1][10] Sales Performance - Sales in the United States rose by 22.6% at constant currency, while the Rest of the World saw an 8.0% increase, and Europe experienced a modest growth of 0.2% [2] - Dupixent, a key product in Immunology, generated sales of €4.25 billion, marking a 32.2% year-over-year increase, with U.S. sales rising by 35.9% [3][10] - Altuviiio, a rare disease drug, recorded sales of €324 million, up 53.0% year over year, with 85% of sales coming from the U.S. market [5] - Nexviazyme/Nexviadzyme sales reached €203 million, up 15.8% year over year, while Myozyme sales declined by 5.3% to €122 million [6] Drug and Vaccine Insights - Cablivi sales increased by 1.4% to €69 million, while Eloctate sales fell by 16.0% to €63 million due to patient switches to Altuviiio [7] - Total vaccine sales declined by 2.5% to €2.04 billion, primarily due to lower sales of certain vaccines, although flu vaccine sales rose by 31.5% to €575 million [14][15] - Sanofi's new drugs, Qfitlia and Wayrilz, generated sales of €4 million and €6 million respectively, with both drugs currently only approved in the U.S. [8][9] Future Outlook - Sanofi provided guidance for 2026, expecting high single-digit sales growth at constant currency and earnings growth to outpace sales growth [16] - The company anticipates a stock buyback worth €1 billion in 2026 [16] - Sanofi's stock has seen a decline of 15.6% over the past year, contrasting with an 18.0% increase in the industry [18] M&A Activity - Sanofi announced an agreement to acquire Dynavax Technologies for approximately $2.2 billion, which will enhance its adult vaccines portfolio [20] - The acquisition of Blueprint Medicines last year has expanded Sanofi's presence in rare immunological diseases [20]